Overview
Novucure develops a technology system that supports clinical trial protocol adherence and communication with patients. It helps schedule visits and procedures, sends reminders, and supports the collection of patient health data between visits; it serves patients, clinics, and clinical trial sponsors.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2024-08-01. Active
17 1050 1953 1000 0090 8182 2745
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 20, 2024 | Aid for SME access to finance — aid for start-ups | $150.2K$150,180 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| May 19, 2022 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $6,159$6,159 | Polska Fundacja Ośrodków Wspomagania Rozwoju Gospodarczego Oic Poland z Siedzibą w Lublinie |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-07-01 | Opracowanie i wdrożenie innowacyjnej platformy wspierającej komunikację pomiędzy pacjentami a podmiotami przeprowadzającymi badania kliniczne | $149.1K$149,084 | Fundusze Europejskie dla Polski Wschodniej 2021-2027 |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Sławomir Kobacki (52) | 35 | $472.72 | 35% |
Natalia Anna Milińska (37) | 65 | $877.90 | 65% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
FAQ
Last updated: 2026-07-17